Research Article
MXRA5 Is a Novel Immune-Related Biomarker That Predicts Poor Prognosis in Glioma
Figure 9
The MXRA5 survival curves of glioma and GBM in the CGGA and TCGA cohorts. Kaplan-Meier survival analysis showed that, compared to low expression, high expression of MXRA5 conferred a significantly worse prognosis in glioma and GBM patients.
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |